These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 3120823

  • 1. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
    Collen D, Stassen JM, Larsen G.
    Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823
    [Abstract] [Full Text] [Related]

  • 2. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB.
    J Biol Chem; 1991 May 05; 266(13):8156-61. PubMed ID: 1708773
    [Abstract] [Full Text] [Related]

  • 3. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 05; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat.
    Larsen GR, Metzger M, Henson K, Blue Y, Horgan P.
    Blood; 1989 May 15; 73(7):1842-50. PubMed ID: 2496774
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
    Cambier P, van de Werf F, Larsen GR, Collen D.
    J Cardiovasc Pharmacol; 1988 Apr 15; 11(4):468-72. PubMed ID: 2453751
    [Abstract] [Full Text] [Related]

  • 6. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.
    Hansen L, Blue Y, Barone K, Collen D, Larsen GR.
    J Biol Chem; 1988 Oct 25; 263(30):15713-9. PubMed ID: 3139674
    [Abstract] [Full Text] [Related]

  • 7. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR, Ahern TJ, Angus LB, Barone KM, Brenner MJ, Horgan PG, Morris GE, Stoudemire JB, Timony GA, Larsen GR.
    J Biol Chem; 1991 Feb 25; 266(6):3715-23. PubMed ID: 1847387
    [Abstract] [Full Text] [Related]

  • 8. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D.
    Blood; 1992 Jan 15; 79(2):417-29. PubMed ID: 1730087
    [Abstract] [Full Text] [Related]

  • 9. Newer thrombolytic agents.
    Verstraete M.
    Ann Acad Med Singap; 1999 May 15; 28(3):424-33. PubMed ID: 10575530
    [Abstract] [Full Text] [Related]

  • 10. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ, Verheijen JH.
    Arzneimittelforschung; 1992 Mar 15; 42(3):358-62. PubMed ID: 1497699
    [Abstract] [Full Text] [Related]

  • 11. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM.
    Thromb Haemost; 1991 Feb 12; 65(2):174-80. PubMed ID: 1905070
    [Abstract] [Full Text] [Related]

  • 12. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 13. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D, Dewerchin M, Rapold HJ, Lijnen HR, Stassen JM.
    Circulation; 1990 Nov 02; 82(5):1744-53. PubMed ID: 2121385
    [Abstract] [Full Text] [Related]

  • 14. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    J Biol Chem; 1990 Apr 05; 265(10):5677-83. PubMed ID: 2156824
    [Abstract] [Full Text] [Related]

  • 15. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D, Lijnen HR, Bulens F, Vandamme AM, Tulinsky A, Nelles L.
    J Biol Chem; 1990 Jul 25; 265(21):12184-91. PubMed ID: 2115513
    [Abstract] [Full Text] [Related]

  • 16. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR, Lijnen HR, Stassen JM, Collen D.
    Blood; 1991 Jul 01; 78(1):125-31. PubMed ID: 1906351
    [Abstract] [Full Text] [Related]

  • 17. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L, Li XK, Vanlinthout I, De Cock F, Lijnen HR, Collen D.
    Thromb Haemost; 1992 Apr 02; 67(4):445-52. PubMed ID: 1631793
    [Abstract] [Full Text] [Related]

  • 18. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
    Clozel JP, Tschopp T, Luedin E, Holvoet P.
    Circulation; 1989 Jan 02; 79(1):125-33. PubMed ID: 2491972
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul 02; 346(1):108-13. PubMed ID: 1407000
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.